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Summary
Background Early menopause is linked to an increased risk of cardiovascular disease mortality; however, the 
association between early menopause and incidence and timing of cardiovascular disease is unclear. We aimed to 
assess the associations between age at natural menopause and incidence and timing of cardiovascular disease.
Methods We harmonised and pooled individual-level data from 15 observational studies done across five countries and 
regions (Australia, Scandinavia, the USA, Japan, and the UK) between 1946 and 2013. Women who had reported their 
menopause status, age at natural menopause (if postmenopausal), and cardiovascular disease status (including coronary 
heart disease and stroke) were included. We excluded women who had hysterectomy or oophorectomy and women who 
did not report their age at menopause. The primary endpoint of this study was the occurrence of first non-fatal 
cardiovascular disease, defined as a composite outcome of incident coronary heart disease (including heart attack and 
angina) or stroke (including ischaemic stroke or haemorrhagic stroke). We used Cox proportional hazards models to 
estimate multivariate hazard ratios (HRs) and 95% CIs for the associations between age at menopause and incident 
cardiovascular disease event. We also adjusted the model to account for smoking status, menopausal hormone therapy 
status, body-mass index, and education levels. Age at natural menopause was categorised as premenopausal or 
perimenopausal, younger than 40 years (premature menopause), 40–44 years (early menopause), 45–49 years (relatively 
early), 50–51 years (reference category), 52–54 years (relatively late), and 55 years or older (late menopause).
Findings Overall, 301 438 women were included in our analysis. Of these 301 438 women, 12 962 (4·3%) had a first non-
fatal cardiovascular disease event after menopause, of whom 9369 (3·1%) had coronary heart disease and 4338 (1·4%) had 
strokes. Compared with women who had menopause at age 50–51 years, the risk of cardiovascular disease was higher 
in women who had premature menopause (age <40 years; HR 1·55, 95% CI 1·38–1·73; p<0·0001), early menopause 
(age 40–44 years; 1·30, 1·22–1·39; p<0·0001), and relatively early menopause (age 45–49 years; 1·12, 1·07–1·18; 
p<0·0001), with a significantly reduced risk of cardiovascular disease following menopause after age 51 years (p<0·0001 
for trend). The associations persisted in never smokers, and were strongest before age 60 years for women with 
premature menopause (HR 1·88, 1·62–2·20; p<0·0001) and early menopause (1·40, 1·27–1·54; p<0·0001), but were 
attenuated at age 60–69 years, with no significant association observed at age 70 years and older.
Interpretation Compared with women who had menopause at age 50–51 years, women with premature and early 
menopause had a substantially increased risk of a non-fatal cardiovascular disease event before the age of 60 years, 
but not after age 70 years. Women with earlier menopause need close monitoring in clinical practice, and age at 
menopause might also be considered as an important factor in risk stratification of cardiovascular disease for women.
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Introduction
Natural menopause, defined as absence of menstruation 
over a period of 12 months,1 typically occurs between the 
ages of 49 and 52 years, but varies among different 
ethnicities,2 with a median age of 51·4 years in high-income 
countries.3,4 Menopause between age 40 and 45 years, 
usually defined as early menopause, occurs in around 
5% of women.5,6 Premature menopause before 40 years 
(also known as primary ovarian insufficiency if periods stop 
spontaneously)6 affects about 1% of women.7
Although early menopause has been linked to an 
increased risk of cardiovascular disease mortality and 
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all-cause mortality,8 few studies have examined the 
associa tions between a broad range of ages at menopause 
and risk of incident cardiovascular disease. For example, 
in a 2016 review and meta-analysis,8 the risk of incident 
cardiovascular disease was compared between women 
with early menopause and women with menopause at 
45 years or older, which included both relatively early 
menopause (at 45–49 years) and late menopause (at 
≥55 years). Women with early menopause (<45 years) 
had a 50% increased risk (relative risk 1·50, 95% CI 
1·28–1·76) of coronary heart disease, whereas the 
association between age at menopause and incident 
stroke was inconsistent.8 Women now live around 
one-third of their life span after menopause,9 and this 
period of time might be even longer for women 
with earlier menopause. In this context, it is useful to 
investigate the association between early or premature 
menopause and the incidence and timing of cardio- 
vascular disease.
We aimed to assess the associations between a broad 
range of ages at natural menopause and incident 
cardiovascular disease, coronary heart disease, and stroke. 
We hypothesised that earlier menopause would lead to 
higher risk and earlier onset of cardiovascular disease 
than menopause at average age or later menopause.
Methods
Study design and participants
The International Collaboration for a Life Course Approach 
to Reproductive Health and Chronic Disease Events 
(InterLACE) is a consortium of pooled individual-level 
data on reproductive health and chronic diseases for 
537 153 women who participated in 25 observational 
studies across ten countries between 1946 and 2013. 
Most studies were of prospective longitudinal design and 
collected survey data on key reproductive, socio- 
demographic, lifestyle factors, and disease outcomes. After 
the studies had joined the InterLACE consortium, 
a harmonisation process was developed to combine 
individual-level data. A detailed description of the 
InterLACE consortium and data harmonisation has been 
published previously.10–12 Data for the present study were 
provided from 15 observational studies done in 
five countries and regions (Australia, Scandinavia, the 
USA, Japan, and the UK; appendix pp 1, 2) between 1946 
and 2013.
We included women who had reported their natural 
menopause status (premenopause, perimenopause, 
and postmenopause), age at natural menopause 
(if postmenopausal), and cardiovascular disease status 
(including coronary heart disease and stroke). Women 
who had hysterectomy or oophorectomy and women who 
reported use of meno pausal hormone therapy or oral 
contraceptives but did not report their age at menopause 
were excluded.
Women who had missing data on key covariates, 
including age at last follow-up, ethnicity, education level, 
body-mass index (BMI), smoking status, hypertension 
status at baseline, or postmenopausal hormone therapy 
status were also excluded (appendix pp 1, 2).
Ethical approval was obtained from the Institutional 
Review Board or Human Research Ethics Committee at 
Research in context
Evidence before this study
We searched PubMed from database inception until 
March 1, 2019, for observational studies published in English, 
using the search terms “menopause”, “final menstrual period”, 
“cardiovascular disease”, “coronary heart disease”, “myocardial 
infarction”, “angina”, and “stroke”. We screened papers by title 
and abstract to identify full-text reports that were relevant 
to the study aims. We also screened citation lists from these 
full-text reports to identify other relevant research. The papers 
cited in this report were selected to be representative of the 
existing evidence base, and are not an exhaustive list of 
relevant research. Our search yielded more than 90 studies. 
We found previous evidence showing that early menopause is 
linked to an increased risk of cardiovascular disease mortality, 
but the associations between a broad range of ages at natural 
menopause (including premature menopause [<40 years]) 
and incidence and timing of first non-fatal cardiovascular 
disease event are unclear.
Added value of this study
To our knowledge, this is the largest study of individual-level 
data to investigate the associations between a broad range 
of ages at menopause (including premature menopause 
[<40 years]) and incident cardiovascular disease, adjusted 
for smoking status, body-mass index, and hormone therapy 
status. This is also the first study to assess the association 
between age at menopause and timing of onset of first 
cardiovascular disease event.
Implications of all the available evidence
Our results show that compared with women who had 
menopause at age 50–51 years, women with premature and 
early menopause had a substantially increased risk of first 
non-fatal cardiovascular disease event before the age of 
60 years, but not after age 70 years. Early or premature 
menopause might be considered an important factor in risk 
stratification of cardiovascular disease for women. Preventive 
measures should consider this association as part of active 
management of cardiovascular disease risk factors for 
women.
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each participating institution, and all participants provided 
written informed consent.
Exposure and outcome variables
We defined age at natural menopause as 12 consecutive 
months or more of amenorrhea that did not result from 
interventions (such as bilateral oophorectomy, hyster-
ectomy, chemotherapy, or radiotherapy). Menopause 
status was assessed at last follow-up or at the first 
occurrence of coronary heart disease or stroke. Women 
who had a cardiovascular disease event before menopause 
or who were premenopausal (ie, women who had a period 
in the past 3 months with no change in regularity) or 
perimenopausal (ie, women who had a period in 
the past 12 months with a change in regularity) at the 
end of follow-up were categorised as pre menopausal 
or perimenopausal. Thus, age at meno pause was categor-
ised as premenopause or perimenopause, younger than 
40 years (premature menopause), 40–44 years (early 
menopause), 45–49 years (relatively early menopause), 
50–51 years (reference category), 52–54 years (relatively 
late menopause), and 55 years or older (late menopause).
The primary endpoint of this study was the occurrence 
of first non-fatal cardiovascular disease, defined as a 
composite outcome of incident coronary heart disease 
(including heart attack and angina) or stroke (including 
ischaemic stroke or haemorrhagic stroke). Physician-
diagnosed cardiovascular disease was self-reported or 
ascertained from hospital medical records. When 
ascertained from hospital records, incident coronary 
heart disease was defined according to International 
Classification of Diseases, 10th Revision (ICD-10) codes 
I21, I22, I23, I24, and I25, or ICD, 9th Revision (ICD-9) 
codes 410, 411, 412, and 413. Incident stroke was defined 
by ICD-10 codes I60, I61, I63, and I64, or ICD-9 codes 
430, 431, 432, 433, and 434.
Covariates
We included the following factors in the analyses 
as covariates according to evidence from previous 
studies:2,13,14 age at last follow-up, ethnicity, years of 
education, BMI, smoking status, hypertension status, 
type 2 diabetes, parity, age at menarche, and pre- 
menopausal use of oral contraceptives, which were 
reported at baseline or at a mid-age survey for birth 
cohort studies. Information about menopausal hormone 
therapy collected after menopause was used to define 
women as users or non-users. We combined ethnicity 
into six categories: white European, white Australian or 
New Zealander, white American or Canadian, Asian, 
Black, and other. Years of education was categorised as 
10 years or less, 11–12 years, and more than 12 years. 
BMI was categorised as less than 18·5 kg/m², 
18·5 to 24·9 kg/m², 25 to 29·9 kg/m², and 30 kg/m² or 
higher. Smoking status was categorised as current, 
former, or never smoker. Hypertension or diabetes 
status was dichotomised as present or absent on the 
basis of self-report at baseline. Parity was categorised as 
0, 1, 2, and 3 or more livebirths. Age at menarche was 
divided into five categories: 11 years or younger, 12, 
13, 14, and 15 years or older. Premenopausal oral 
contraceptive use was classified as ever use or non-use.
Statistical analysis
Baseline characteristics were presented as means and 
SDs for continuous variables and as percentages for 
categorical variables. We used Cox proportional hazards 
models to estimate hazard ratios (HRs) and 95% CIs. 
The proportional hazards assumption was checked 
using log cumulative hazard plots and seemed to be 
reasonable. Study level variability was included in the 
model as a random effect. Because women who had 
early menopause might have a longer follow-up time 
than those with later menopause and the entry age for 
each study in the InterLACE consortium varied, we 
used the minimum age at natural menopause (32 years) 
as a fixed baseline age for women in all studies to avoid 
left-truncation bias. For women who had a cardiovascular 
disease event, follow-up time was calculated as their age 
at first cardiovascular disease event minus 32 years; for 
women without a cardiovascular disease event, follow-
up time was defined as their age at last follow-up minus 
32 years. For postmenopausal women, the time between 
age 32 years and menopause was classified as the 
unexposed period to account for immortal time 
bias. Menopause at age 50–51 years was used as the 
reference category.
We first analysed all incident cardiovascular disease, 
followed by separate analyses for incident coronary heart 
disease and stroke. To examine whether women 
with earlier menopause had higher risk of incident 
cardiovascular disease at a younger age than those with 
later menopause, we stratified analyses by age at follow-up 
(<60 years, 60–69 years, and ≥70 years). HRs and 95% CIs 
were adjusted for age at last follow-up, ethnicity, education 
level, BMI, smoking status, hypertension status, meno- 
pausal hormone therapy use after menopause, and oral 
contraceptive use in the premenopausal group. Since age 
at menarche and parity were also potential con founders, 
the models were additionally adjusted for these covariates 
using a subset of the available studies.
To quantify dose-response relationships, we used 
restricted cubic spline models to examine the associations 
between age at menopause and incident cardiovascular 
disease; age at menopause was considered a continuous 
variable to estimate the effect of each year of decrease in 
age at natural menopause. We analysed the combined 
effects of age at menopause and menopausal hormone 
therapy use. In a subset of studies that collected time of 
initiation of menopausal hormone therapy and duration 
of meno pausal hormone therapy at women’s last follow-
up, we further examined the effects of age at menopause 
with different duration of menopausal hormone therapy 
(<10 and ≥10 years) and different time of initiation of 
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Age at natural menopause Incident cardiovascular disease
Premenopausal or 
perimenopausal 
(n=108 913)
<40 years 
(n=3424)
40–44 years 
(n=14 038)
45–49 years 
(n=48 061)
50–51 years 
(n=47 391)
52–54 years 
(n=50 996)
≥55 years 
(n=28 662)
No 
(n=287 231)
Yes 
(n=14 254)
Ethnicity
White Australian 
or New Zealander
351 (0·3%) 300 (8·8%) 1084 (7·7%) 3451 (7·2%) 3552 (7·5%) 3655 (7·2%) 2258 (7·9%) 12 974 (4·5%) 1677 (11·8%)
White European 65 402 (60·1%) 2905 (84·8%) 12 070 (86·0%) 40 410 (84·1%) 40 178 (84·8%) 43 924 (86·1%) 25 073 (87·5%) 218 482 (76·1%) 11 480 (80·5%)
White American 
or Canadian
476 (0·4%) 7 (0·2%) 47 (0·3%%) 382 (0·8%) 404 (0·9%) 497 (1·0%) 177 (0·6%) 1893 (0·7%) 97 (0·7%)
Asian 39 729 (36·5%) 131 (3·8%) 510 (3·6%) 2669 (5·6%) 2376 (5·0%) 2073 (4·1%) 711 (2·5%) 47 626 (16·6%) 573 (4·0%)
Black 1844 (1·7%) 53 (1·6%) 212 (1·5%) 740 (1·5%) 535 (1·1%) 522 (1·0%) 293 (1·0%) 3920 (1·4%) 279 (2·0%)
Other 1111 (1·0%) 28 (0·8%) 115 (0·8%) 409 (0·9%) 346 (0·7%) 325 (0·6%) 150 (0·5%) 2336 (0·8%) 148 (1·0%)
Body-mass index
Underweight 
(<18·5 kg/m²)
6332 (5·8%) 108 (3·2%) 326 (2·3%) 1135 (2·4%) 963 (2·0%) 836 (1·6%) 374 (1·3%) 9694 (3·4%) 380 (2·7%)
Normal 
(18·5–24·9 kg/m²)
65 785 (60·4%) 1392 (40·7%) 5959 (42·5%) 22 259 (46·3%) 22 000 (46·4%) 22 741 (44·6%) 11 004 (38·4%) 146 008 (50·8%) 5132 (36·0%)
Overweight 
(25·0–29·9 kg/m²)
24 082 (22·1%) 1113 (32·5%) 4873 (34·7%) 15 835 (33·0%) 15 969 (33·7%) 17 848 (35·0%) 10 936 (38·2%) 85 840 (29·9%) 4816 (33·8%)
Obese 
(≥30 kg/m²)
12 714 (11·7%) 811 (23·7%) 2880 (20·5%) 8832 (18·4%) 8459 (17·9%) 9571 (18·8%) 6348 (22·2%) 45 689 (15·9%) 3926 (27·5%)
Smoking status
Never 69 794 (64·1%) 1709 (49·9%) 7172 (51·1%) 25 829 (53·7%) 27 472 (58·0%) 30 492 (59·8%) 17 372 (60·6%) 173 013 (60·2%) 6827 (47·9%)
Past smoker 24 003 (22·0%) 1080 (31·5%) 4565 (32·5%) 15 049 (31·3%) 14 809 (31·3%) 15 980 (31·3%) 9382 (32·7%) 79 928 (27·8%) 4940 (34·7%)
Current smoker 15 116 (13·9%) 635 (18·6%) 2301 (16·4%) 7183 (15·0%) 5110 (10·8%) 4524 (8·9%) 1908 (6·7%) 34 290 (11·9%) 2487 (17·5%)
Education level (years)
≤10 24 475 (22·5%) 1926 (56·3%) 7367 (52·5%) 22 204 (46·2%) 21 860 (46·1%) 22 896 (44·9%) 14 195 (49·5%) 107 353 (37·4%) 7570 (53·1%)
11–12 13 367 (12·3%) 410 (12·0%) 1546 (11·0%) 5483 (11·4%) 5575 (11·8%) 6293 (12·3%) 3297 (11·5%) 34 446 (12·0%) 1525 (10·7%)
>12 71 071 (65·3%) 1088 (31·8%) 5125 (36·5%) 20 374 (42·4%) 19 956 (42·1%) 21 807 (42·8%) 11 170 (39·0%) 145 432 (50·6%) 5159 (36·2%)
Age at last follow-up (years)
<60 108 913 (100%) 1724 (50·4%) 6329 (45·1%) 24 334 (50·6%) 21 373 (45·1%) 21 785 (42·7%) 6654 (23·2%) 187 134 (65·2%) 3951 (27·7%)
60–64 .. 794 (23·2%) 3573 (25·5%) 11 009 (22·9%) 12 942 (27·3%) 15 570 (30·5%) 12 176 (42·5%) 52 808 (18·4%) 3281 (23·0%)
65–69 .. 612 (17·9%) 2877 (20·5%) 8750 (18·2%) 9214 (19·4%) 9744 (19·1%) 7792 (27·2%) 35 282 (12·3v) 3709 (26·0%)
≥70 .. 294 (8·6%) 1259 (9·0%) 3968 (8·3%) 3862 (8·2%) 3897 (7·6%) 2040 (7·1%) 12 007 (4·2%) 3313 (23·3%)
Hypertension
No 99 482 (91·3%) 2581 (75·4%) 10 494 (74·8%) 37 069 (77·1%) 35 968 (75·9%) 38 137 (74·8%) 20 165 (70·4%) 236 457 (82·3%) 7439 (52·2%)
Yes 9431 (8·7%) 843 (24·6) 3544 (25·3%) 10 992 (22·9%) 11 423 (24·1%) 12 859 (25·2%) 8497 (29·7%) 50 774 (17·7%) 6815 (47·8%)
Postmenopausal menopausal hormone therapy
No 105 459 (96·8%) 1478 (43·2%) 7202 (51·3%) 29 284 (60·9%) 30 232 (63·8%) 32 597 (63·9%) 16 194 (56·5%) 213 791 (74·4%) 8655 (60·7%)
Yes 3454 (3·25) 1946 (56·8%) 6836 (48·7%) 18 777 (39·1%) 17 159 (36·2%) 18 399 (36·1%) 12 468 (43·5%) 73 440 (25·6%) 5599 (39·3%)
Number of children
0 27 897 (26·1%) 756 (22·5%) 2668 (19·2%) 8879 (18·7%) 7795 (16·6%) 7337 (14·5%) 3574 (12·6%) 56 880 (20·1%) 2026 (14·5%)
1 15 038 (14·1%) 517 (15·4%) 1992 (14·4%) 6365 (13·4%) 5752 (12·3%) 5892 (11·7%) 3136 (11·0%) 36 853 (13·0%) 1839 (13·1%)
2 40 623 (38·0%) 1238 (36·9%) 5513 (39·8%) 19 768 (41·7%) 20 249 (43·2%) 22 594 (44·7%) 13 086 (46·0%) 117 824 (41·6%) 5247 (37·4%)
≥3 23 410 (21·9%) 849 (25·3%) 3695 (26·6%) 12 439 (26·21%) 13 107 (27·9%) 14 733 (29·1%) 8663 (30·4%) 71 988 (25·4%) 4908 (35·0%)
Age at menarche (years)
≤11 20 331 (19·1%) 764 (23·1%) 2818 (20·8%) 8296 (17·9%) 7837 (17·1%) 8577 (17·4%) 5328 (19·2%) 51 338 (18·4%) 2613 (19·4%)
12 25 699 (24·1%) 577 (17·4%) 2537 (18·7%) 8992 (19·4%) 8898 (19·5%) 9753 (19·7%) 5139 (18·5%) 59 143 (21·2%) 2452 (18·2%)
13 27 900 (26·1%) 742 (22·4%) 3138 (23·1%) 11 777 (25·4%) 11 809 (25·8%) 12 838 (26·0%) 6698 (24·1%) 71 753 (25·7%) 3149 (23·4%)
14 19 945 (18·7%) 612 (18·5%) 2700 (19·9%) 9430 (20·3%) 9495 (20·8%) 10 350 (21·0%) 5693 (20·5%) 55 501 (19·9%) 2724 (20·2%)
≥15 12 871 (12·1%) 613 (18·5%) 2368 (17·5%) 7914 (17·0%) 7694 (16·8%) 7919 (16·0%) 4968 (17·9%) 41 816 (15·0%) 2531 (18·8%)
Data are n (%).
Table 1: Baseline characteristics by age at natural menopause and incident cardiovascular disease events
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menopausal hormone therapy. We analysed the combined 
effects of age at menopause, smoking status, and BMI 
levels on the risk of incident cardiovascular disease. We 
also examined the role of socioeconomic status by 
analysing the combined effect of age at menopause and 
education level.
We did eight sensitivity analyses to test the robustness 
of our findings. We first analysed data from a subset of 
studies in which cardiovascular disease events were 
ascertained from hospital data, rather than only self-
report. Second, because the UK Biobank contributed 
more than 50% of the total cardiovascular disease 
events, we did an analysis excluding this study. Third, 
we only included cardiovascular disease events which 
occurred at least 3 years after menopause. Fourth, 
we also analysed the associations between age at 
menopause and specific types of coronary heart disease 
(heart attack or angina) and subtype of stroke (ischaemic 
stroke or haemorrhagic stroke). Fifth, we compared 
women’s characteristics in the complete dataset and 
dataset with missing values, and did 10 times multiple 
imputation to impute missing covariates. Sixth, we 
further adjusted for type 2 diabetes in a subset of 
studies. Seventh, we assessed heterogeneity between 
countries and regions (Australia, Scandinavia, the USA, 
Japan, and the UK) using country-specific random-
effects meta-analysis, and I² and p values were used to 
assess heterogeneity. Eighth, we further adjusted for 
family history of cardio- vascular disease in studies with 
relevant information.
We used SAS (version 9.4) in all statistical analyses. The 
PHREG procedure was used to fit the Cox proportional 
hazards regression models. A two-sided p value of 0·05 or 
less was considered to indicate statistical significance.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and final responsibility for the decision to 
submit for publication.
Results
Our analysis included 301 438 women from 15 studies.12,15–28 
The mean (SD) age at last follow-up was 57·0 years (10·3) 
and more than half of the women were born after 1950. 
192 525 (64·0%) of 301 438 were postmenopausal at the 
end of follow-up (table 1; appendix p 1). The mean age at 
menopause was 50·2 years (SD 4·4), and the median 
age was 50·0 years (IQR 48·0–53·0). 3424 (1·2%) of 
301 438 women had premature menopause and 
14 038 (4·7%) had early menopause. The mean time from 
menopause to incident cardiovascular disease was 
13·5 years (SD 9·0), with a median time of 12·0 years 
(6·0–19·6). 12 962 (4·3%) of 301 438 women had non-
fatal cardiovascular disease events after menopause, 
including 9369 (3·1%) coronary heart disease events and 
4338 (1·4%) strokes. Compared with women who did not 
have a cardiovascular disease event, those who had a 
cardiovascular disease event were more likely to be less 
educated, obese, and current smokers with a history of 
hypertension (table 1).
Compared with women who had menopause at 
50–51 years, risk of cardiovascular disease was higher 
among women with premature (HR 1·55, 95% CI 
1·38–1·73; p<0·0001), early (1·30, 1·22–1·39; p<0·0001), 
or relatively early menopause (1·12, 1·07–1·18; p<0·0001). 
By contrast, risk of cardiovascular disease was lower in 
women with late menopause (0·88, 0·83–0·93; p<0·0001) 
Women (n) Cardiovascular 
disease events 
(n)
Person-years 
(n)
Events per 
1000 
person-years 
(n)
Adjusted HR 
(95% CI)*
Cardiovascular disease
Age at natural menopause (years)
<40 3424 346 84 961·6 4·1 1·55 (1·38–1·73)
40–44 14 038 1216 372 142·8 3·3 1·30 (1·22–1·39)
45–49 48 061 3316 1 269 834·9 2·6 1·12 (1·07–1·18)
50–51 47 391 3016 1 303 876·1 2·3 1 (ref)
52–54 50 996 3146 1 429 883·3 2·2 0·96 (0·91–1·01)
≥55 28 662 1922 852 776·4 2·3 0·88 (0·83–0·93)
Premenopause or 
perimenopause
108 913 3253 2 842 537·1 1·1 0·52 (0·48–0·56)
Trend p value† ·· ·· ·· ·· <0·0001
Coronary heart disease
Age at natural menopause (years)
<40 3419 253 85 414·1 3·0 1·52 (1·34–1·74)
40–44 14 022 881 373 417·4 2·4 1·30 (1·20–1·41)
45–49 48 016 2418 1 272 920·1 1·9 1·13 (1·06–1·20)
50–51 47 362 2180 1 307 497·1 1·7 1 (ref)
52–54 50 944 2260 1 432 324·2 1·6 0·96 (0·90–1·02)
≥55 28 628 1377 854 420·9 1·6 0·90 (0·85–0·97)
Premenopause or 
perimenopause
108 902 2229 2 710 689·7 0·8 0·59 (0·53–0·65)
Trend p value† ·· ·· ·· ·· <0·0001
Stroke
Age at natural menopause (years)
<40 3412 126 86 474·8 1·5 1·72 (1·43–2·07)
40–44 13 993 416 376 099·8 1·1 1·32 (1·18–1·48)
45–49 47 892 1078 1 279 465·0 0·8 1·09 (1·00–1·18)
50–51 47 301 1018 1 31 4206·0 0·8 1 (ref)
52–54 50 868 1048 1 439 717·0 0·7 0·94 (0·86–1·02)
≥55 28 644 652 860 938·3 0·8 0·89 (0·81–0·99)
Premenopause or 
perimenopause
108 805 1120 2 065 658·4 0·5 0·46 (0·40–0·52)
Trend p value† ·· ·· ·· ·· <0·0001
HR=hazard ratio. *Cox proportional hazards models were used to estimate HRs and 95% CIs. All HRs were 
adjusted for age at last follow-up, ethnicity, education level, body-mass index, smoking status, hypertension status, 
and postmenopausal menopausal hormone therapy status, or oral contraception use in the premenopause or 
perimenopause group. †χ² values of >50, with 6 degrees of freedom.
Table 2: Associations between age at natural menopause and first non-fatal cardiovascular disease, 
coronary heart disease, and stroke events
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and women who were premenopausal or perimenopausal 
(0·52, 0·48–0·56; p<0·0001) at last follow-up (p<0·0001 
for trend; table 2). Similar associations were observed 
when incident coronary heart disease and stroke were 
analysed separately. The estimates remained largely 
similar when the model was adjusted for age at menarche 
and parity (based on data from 12 studies,12,15–26 data 
not shown). The cubic spline models showed an 
approximately linear relationship between age at 
menopause and risk of incident cardiovascular disease, 
coronary heart disease, and stroke (figure 1). When we 
analysed age at menopause as a continuous variable, each 
year of decrease in age was associated with a 3% increased 
risk of incident cardiovascular disease (1·03, 1·02–1·04; 
p<0·0001).
Compared with women who had menopause at 
50–51 years, women with premature menopause 
(1·88, 1·62–2·20; p<0·0001), early menopause 
(1·40, 1·27–1·54; p<0·0001), or relatively early meno-
pause (1·17, 1·09–1·25; p=0·0002) had the highest excess 
risk of first non-fatal cardiovascular disease event before 
the age of 60 years, with only modest associations at age 
60–69 years, and no significant associations at older ages 
(≥70 years; table 3).
When we combined age at menopause and post- 
menopausal menopausal hormone therapy status, 
women who had premature menopause and used 
menopausal hormone therapy had a similar risk of 
coronary heart disease compared with women who did 
not use menopausal hormone therapy (HR 1·64, 
1·35–1·99; p<0·0001 vs 1·62, 1·36–1·93; p<0·0001); 
however, women who had premature menopause and 
used menopausal hormone therapy had higher risk of 
stroke (2·06, 1·52–2·52; p<0·0001) than women who 
did not report the use of menopausal hormone therapy 
(1·45, 1·11–1·89; p=0·0067; figure 2; appendix p 3). 
Further analyses of seven studies12,15,16,21–24 that collected 
time of initiation of menopausal hormone therapy and 
duration of menopausal hormone therapy at women’s 
last follow-up suggested that women with premature or 
early menopause who used menopausal hormone 
therapy for longer than 10 years had the lowest risk of 
cardiovascular disease when compared with women 
with early or premature menopause who did not use 
menopausal hormone therapy and women with early or 
premature menopause who used menopausal hormone 
therapy for less than 10 years. Additionally, among these 
women, those who had initiated menopausal hormone 
therapy 1 year after menopause had the lowest risk of 
cardiovascular disease when compared with women 
who did not use menopausal hormone therapy and 
women who initiated menopausal hormone therapy 
more than 1 year after menopause (appendix pp 4, 5). 
Women who initiated menopausal hormone therapy 
after age 60 years had higher HRs than those who started 
menopausal hormone therapy before age 60 years 
(appendix pp 4, 5). Analyses stratified by smoking status 
showed that the effects of premature or early menopause 
on incident cardiovascular disease were stronger among 
former and current smokers than never smokers 
(figure 3; appendix pp 6, 7). However, compared with the 
overall HRs (table 2), HRs among never smokers were 
only slightly attenuated (p<0·0001) showing decreasing 
risk of cardiovascular disease with increasing age at 
natural menopause (figure 3; appendix pp 6, 7). 
Underweight women and women with obesity with 
earlier menopause had a higher risk of incident 
cardiovascular disease than did those with normal BMIs 
(appendix p 8). Furthermore, poorly educated women 
with earlier menopause had a higher risk of incident 
cardiovascular disease than those who were more highly 
educated (appendix p 9).
Figure 1: Association between age at natural menopause and first 
cardiovascular events
Association between age at menopause and incident cardiovascular disease (A), 
coronary heart disease (B), and stroke (C). Restricted cubic spline models were 
used to visualise the shape. HR=hazard ratio.
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When only cardiovascular disease cases ascertained by 
hospital record were analysed (three studies12,18,19), results 
were similar to the main analysis (appendix p 10). After 
excluding the UK Biobank study,12 associations between 
earlier menopause and risk of cardiovascular disease also 
remained largely unchanged (appendix p 11). When only 
cardiovascular disease events that occurred at least 3 years 
after menopause were included, we found the associations 
were strengthened (appendix p 12). Furthermore, the 
associations remained unchanged when age at menopause 
was stratified by subtype of coronary heart disease (data 
from MCCS,17 DNC,18 WLH,19 NSHD,23 ELSA,25 UKWCS,26 
WHITEHALL II,27 SWAN,21 JNHS,22 SABRE,28 and UK 
Biobank12 studies) and stroke (data from WLH19 and UK 
Aged <60 years at first event Aged 60–69 years at first event Aged ≥70 years at first event
Cardiovascular 
disease events 
(n)
Events per 
1000 
person-years 
(n)
Adjusted HR 
(95% CI)
Cardiovascular 
disease events 
(n)
Events per 
1000 
person-years 
(n)
Adjusted HR 
(95% CI)
Cardiovascular 
disease events 
(n)
Events per 
1000 
person-years 
(n)
Adjusted HR 
(95% CI)
Cardiovascular disease
Age at natural menopause (years)
<40 193 2·5 1·88 
(1·62–2·20)
99 2·0 1·35 
(1·10–1·66)
54 3·9 1·14 
(0·86–1·52)
40–44 597 1·8 1·40 
(1·27–1·54)
413 1·8 1·30 
(1·16–1·46)
206 3·2 1·09 
(0·93–1·27)
45–49 1634 1·4 1·17 
(1·09–1·25)
1035 1·4 1·08 
(0·99–1·17)
647 3·2 1·09 
(0·97–1·22)
50–51 1472 1·3 1 (ref) 986 1·2 1 (ref) 558 2·7 1 (ref)
52–54 1523 1·2 0·91 
(0·85–0·98)
1065 1·2 0·99 
(0·91–1·08)
558 2·8 1·02 
(0·91–1·15)
≥55 875 1·2 0·82 
(0·75–0·89)
729 1·1 0·91 
(0·83–1·00)
318 2·8 1·07 
(0·93–1·23)
Trend p value ·· ·· <0·0001 ·· ·· <0·0001 ·· ·· 0·0342
Coronary heart disease
Age at natural menopause (years)
<40 139 1·8 1·85 
(1·48–2·10)
79 1·5 1·44 
(1·14–1·81)
35 2·5 1·03 
(0·73– ·46)
40–44 423 1·3 1·38 
(1·23–1·54)
307 1·3 1·33 
(1·16–1·52)
151 2·3 1·06 
(0·88–1·27)
45–49 1195 1·1 1·19 
(1·10–1·30)
768 1·0 1·11 
(1·00–1·22)
455 2·2 1·02 
(0·89–1·17)
50–51 1052 0·9 1 (ref) 713 0·9 1 (ref) 415 2·0 1 (ref)
52–54 1111 0·9 0·93 
(0·86–1·01)
763 0·9 0·99 
(0·89–1·10)
386 1·9 0·96 
(0·84–1·10)
≥55 653 0·9 0·86 
(0·78–0·95)
522 0·8 0·92 
(0·82–1·03)
202 1·7 0·93 
(0·79–1·11)
Trend p value ·· ·· <0·0001 ·· ·· <0·0001 ·· ·· 0·0046
Stroke
Age at natural menopause (years)
<40 62 0·8 1·93 
(1·48–2·52)
32 0·6 1·32 
(0·91–1·89)
32 2·0 1·73 
(1·19–2·52)
40–44 199 0·6 1·44 
(1·22–1·70)
133 0·5 1·23 
(1·01–1·50)
84 1·2 1·17 
(0·91–1·51)
45–49 509 0·4 1·11 
(0·98–1·26)
318 0·4 0·99 
(0·85– 1·15)
251 1·2 1·15 
(0·95–1·38)
50–51 484 0·4 1 (ref) 332 0·4 1 (ref) 202 0·9 1 (ref)
52–54 467 0·4 0·85 
(0·75–0·96)
358 0·4 0·98 
(0·85–1·14)
223 1·0 1·10 
(0·91–1·33)
≥55 249 0·3 0·71 
(0·60–0·82)
251 0·4 0·90 
(0·76–1·06)
152 1·2 1·38 
(1·12–1·71)
Trend p value ·· ·· <0·0001 ·· ·· 0·0051 ·· ·· 0·3826
HR=hazard ratio. *Cox proportional hazards models were used to estimate HRs and 95% CIs. All HRs were adjusted for age at last follow-up, ethnicity, education level, 
body-mass index, smoking status, hypertension status, and postmenopausal menopausal hormone therapy status.
Table 3: Associations between age at natural menopause and age at first cardiovascular disease, coronary heat disease, and stroke events*
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Biobank12 studies; appendix p 13). Overall, the character-
istics of women with complete datasets and missing 
datasets were comparable. The adjusted HRs (95% CIs) 
were similar for complete case analyses and multiple 
imputation-based analyses and after adjustment for type 2 
diabetes (data from 12 studies [ALSWH,15 HOW,16 MCCS,17 
DNC,18 SWAN,21 NSHD,23 NCDS,24 ELSA,25 UKWCS,26 
WHITEHALL II,27 SABRE,28 and UK Biobank12 studies; 
appendix pp 14–16). Country-specific random-effects meta-
analyses revealed no significant heterogeneity between 
countries (data not shown). When only studies with 
available data on family history of cardiovascular disease 
were included in the model (HOW,16 DNC,18 UKWCS,26 
WHITEHALL II,27 JNHS,22 and UK Biobank12 studies), the 
results remained unchanged (data not shown).
Discussion
The risk of non-fatal cardiovascular disease events 
was more than 1·5 times higher among women with 
premature menopause (<40 years) and 1·3 times higher 
among women with early menopause (40–44 years) than 
women who had natural menopause at 50–51 years. 
Additionally, the risk of experiencing a cardiovascular 
disease before the age of 60 years was around two times 
higher among women with premature menopause and 
1·4 times higher among women with early menopause 
than women in the reference group.
Although short reproductive duration29 and surgical 
menopause have been shown to increase the risk of 
coronary heart disease,30 data on the association between 
earlier natural menopause and incident cardiovascular 
disease have been inconsistent.31 In one study, early 
menopause was associated with an approximately 
two times higher risk of a coronary heart disease event, but 
after adjusting for family history of coronary heart disease, 
the association was not statistically significant (HR 1·80, 
95% CI 0·99–3·29); this study included both women with 
early natural and surgical menopause.32 In the Nurses’ 
Health Study,33 the relative risk of 1·04 (95% CI 1·01–1·07) 
of coronary heart disease for each year of decrease in age at 
natural menopause was only observed for current smokers. 
Also, in the DNC study,34 a significant association was 
found between premature menopause and risk of coronary 
heart disease (HR 2·2, 1·0–4·9), but the association was 
not statistically significant when women were stratified by 
menopausal hormone therapy use.
We found that both premature and early menopause 
were associated with a higher risk of first coronary heart 
disease event when menopause at 50–51 years was used as 
the reference group, which is consistent with the results 
from two previous studies.29,35 An approximately linear 
relationship was observed, with a 3% increased risk of 
incident coronary heart disease per 1 year decrease in age 
at menopause, which is consistent with the results of a 
previous study.36 The association remained unchanged 
when family history of cardiovascular disease was included 
in the statistical model and was not materially affected by 
smoking or menopausal hormone therapy status. In the 
Women’s Health Initiative study, women who began 
menopausal hormone therapy before age 60 years had a 
lower risk of coronary heart disease than those who began 
therapy after age 60 years, while no association was 
observed for stroke.37 However, the Women’s Health 
Initiative studies included older women (mean age 
63·2 years) and the results might be generalisable to 
women with premature or early menopause.37
Existing literature on the association between age at 
natural menopause and risk of stroke is inconclusive.8,38 
In three cohort studies, premature and early menopause 
were not significantly associated with risk of ischaemic 
or haemorrhagic stroke.33,39,40 However, two studies33,40 
only included women who never used menopausal 
hormone therapy, and one40 had only a small number of 
stroke events. In the Framingham cohort study, women 
with natural menopause before age 42 years had twice 
the risk of ischaemic stroke compared with women with 
natural menopause later than 42 years; this association 
Figure 2: Combined effect of age at menopause and menopausal hormone therapy on risk of incident 
cardiovascular disease, coronary heart disease, and stroke events
Cox proportional hazards models were used to estimate HRs and 95% CIs. HRs were adjusted for age at last 
follow-up, ethnicity, education level, body-mass index, smoking status, and hypertension status. n=number 
of events. N=number of participants. HR=hazard ratio. MHT=menopausal hormone therapy.
HR (95% CI) p valuen/N
 Cardiovascular disease
 <40 years + MHT
 <40 years + no MHT
 40–44 years + MHT
 40–44 years + no MHT
 45–49 years + MHT
 45–49 years + no MHT
 50–51 years + MHT
 50–51 years + no MHT
 52–54 years + MHT
 52–54 years + no MHT
 ≥55 years + MHT
 ≥55 years + no MHT
 Coronary heart disease
 <40 years + MHT
 <40 years + no MHT
 40–44 years + MHT
 40–44 years + no MHT
 45–49 years + MHT
 45–49 years + no MHT
 50–51 years + MHT
 50–51 years + no MHT
 52–54 years + MHT
 52–54 years + no MHT
 ≥55 years + MHT
 ≥55 years + no MHT
 Stroke
 <40 years + MHT
 <40 years + no MHT
 40–44 years + MHT
 40–44 years + no MHT
 45–49 years + MHT
 45–49 years + no MHT
 50–51 years + MHT
 50–51 years + no MHT
 52–54 years + MHT
 52–54 years + no MHT
 ≥55 years + MHT
 ≥55 years + no MHT
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Figure 3: Combined effect of age at menopause and smoking status on risk of incident cardiovascular disease, coronary heart disease, and stroke
Cox proportional hazards models were used to estimate HRs and 95% CIs. All HRs were adjusted for age at last follow-up, ethnicity, education level, body-mass index, 
hypertension status, and postmenopausal menopausal hormone therapy status or oral contraception use in the premenopause or perimenopause group. n=number 
of events. N=number of participants. HR=hazard ratio.
HR (95% CI) p valuen/N
 Cardiovascular disease
 <40 years + current smoker
 40–44 years + current smoker
 45–49 years + current smoker
 50–51 years + current smoker
 52–54 years + current smoker
 ≥55 years + current smoker
 Premenopause or perimenopause + current smoker
 <40 years + former smoker
 40–44 years + former smoker
 45–49 years + former smoker
 50–51 years + former smoker
 52–54 years + former smoker
 ≥55 years + former smoker
 Premenopause or perimenopause + former smoker
 <40 years + never smokers
 40–44 years + never smoker
 45–49 years + never smoker
 50–51 years + never smoker
 52–54 years + never smoker
 ≥55 years + never smoker
 Premenopause or perimenopause + never smoker
 Coronary heart disease
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 52–54 years + current smoker
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 Premenopause or perimenopause + current smoker
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 45–49 years + former smoker
 50–51 years + former smoker
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 Stroke
 <40 years + current smoker
 40–44 years + current smoker
 45–49 years + current smoker
 50–51 years + current smoker
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 40–44 years + former smoker
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 0·51 (0·46–0·56)
 3·12 (2·40–4·04)
 2·54 (2·20–2·95)
 1·93 (1·74–2·15)
 1·86 (1·65–2·09)
 1·64 (1·45–1·86)
 1·62 (1·36–1·93)
 1·31 (1·14–1·51)
 2·35 (1·89–2·92)
 1·73 (1·52–1·97)
 1·56 (1·43–1·71)
 1·36 (1·24–1·49)
 1·33 (1·22–1·46)
 1·24 (1·12–1·38)
 0·89 (0·74–1·07)
 1·80 (1·47–2·20)
 1·35 (1·20–1·52)
 1·16 (1·06–1·26)
   (ref)
 1·00 (0·92–1·09)
 1·00 (0·91–1·10)
 0·66 (0·54–0·80)
 3·41 (2·39–4·84)
 2·26 (1·81–2·81)
 1·82 (1·56–2·13)
 1·65 (1·39–1·96)
 1·47 (1·22–1·77)
 1·70 (1·32–2·18)
 0·86 (0·77–0·95)
 2·61 (1·94–3·50)
 1·64 (1·36–1·98)
 1·37 (1·20–1·57)
 1·32 (1·15–1·51)
 1·29 (1·13–1·47)
 1·07 (0·91–1·26)
 0·52 (0·45–0·59)
 1·53 (1·12–2·07)
 1·39 (1·17–1·64)
 1·08 (0·95–1·23)
   (ref)
 0·98 (0·87–1·11)
 1·06 (0·93–1·22)
 0·41 (0·35–0·49)
0 3·0 5·01·0
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persisted in never smokers and non-menopausal 
hormone therapy users.41 Consistent with two recent 
studies,29,35 we found premature and early menopause 
were similarly associated with both ischaemic and 
haemorrhagic stroke. We also found that menopausal 
hormone therapy users had a higher risk of incident 
stroke than non-users. A recent Cochrane review also 
found a 24% increased risk of stroke following use of 
menopausal hormone therapy prescribed for primary or 
secondary prevention of cardiovascular disease.42
One of our main findings was that the excess risk of 
cardiovascular disease following premature or early 
menopause was largely confined to events occurring at 
ages younger than 70 years and was highest before the 
age of 60 years. Few studies have examined in detail the 
association between age at menopause and timing of 
onset of cardio vascular disease events. In one study, 
women with earlier menopause had higher risk of 
cardiovascular mortality at age 65 years than those with 
later menopause.43 However, this study did not include 
non-fatal cardiovascular disease. Our findings might 
help to identify women at high risk of cardiovascular 
disease at an early age. Additionally, the J-shaped curve 
observed for risk of stroke after age 70 years might arise 
because more than 50% of women in this age group 
were overweight or obese, and a J-shaped curve has been 
found between overweight BMI and age at natural 
menopause.14
Several mechanisms have been proposed to explain the 
association between earlier menopause and increased risk 
of postmenopausal cardiovascular disease. Endogenous 
oestrogens have protective effects on the cardiovascular 
system.44 Oestrogen increases vasodilatation45 and inhibits 
the response of blood vessels to injury and the development 
of atherosclerosis.44 Early loss of oestrogen might 
impair vascular function and increase the expression of 
inflammatory cytokines at younger ages, which might 
further damage the vascular function.46 Circulating 
androgen and sex hormone-binding globulin concen-
trations are also associated with risk of cardiovascular 
disease.47 High concentrations of androgen and low 
concentrations of sex hormone-binding globulin are 
associated with both risk of postmenopausal cardiovascular 
disease events48 and adverse cardiovascular disease risk 
factor profiles. Additionally, genetic or environmental 
factors need to be considered. An adverse cardiovascular 
disease risk factor profile in premenopausal women might 
be associated with both earlier menopause and occurrence 
of cardiovascular disease.49 Also, the changes in cardio- 
vascular disease risk factors (eg, lipid concen trations), 
which coincide with the oestrogen reduction during the 
menopausal transition, might contribute to risk of 
cardiovascular disease, although no consistent conclu- 
sions have been reported in the literature.50,51
The main strength of our study was the large sample of 
pooled individual-level data, which was obtained from 
15 studies across different geographical regions and 
populations, representing many different ethnic groups. 
The participant-level data in InterLACE enabled us to 
harmonise variables using common definitions, coding, 
and cutoff points, which is not usually possible with 
meta-analyses of published results.
Our study also has several limitations. First, about 
40% of postmenopausal cardiovascular disease events 
were self-reported but consistent findings were observed 
in analyses confined to cardiovascular disease events 
ascertained through medical records. Second, smoking 
is a well-known shared risk factor for early menopause 
and cardiovascular disease13 and BMI is another 
modifiable variable associated with both age at 
menopause and cardiovascular disease.14 Additionally, 
postmenopausal menopausal hormone therapy status 
might mediate the association between age at 
menopause and cardiovascular disease.42 We used 
variables reported at middle age (41–53 years) and 
postmenopausal menopausal hormone therapy status at 
a specific timepoint as covariates rather than treating 
them as time-varying covariates, which could have 
caused some bias. However, of the studies included in 
InterLACE that included women who reported smoking 
status and BMI levels both before and after menopause 
(ie, UK Biobank,12 NSHD,23 NCDS,24 SWAN,21 and 
SABRE28), the concordance rate was approximately 85%. 
Additionally, around 80% of women used menopausal 
hormone therapy for more than 6 years.52 Thus, we 
assume the bias caused by not using time-varying 
covariates is small. Third, information about post- 
menopausal lipid concentrations was not available, 
which might mediate the association between age at 
natural menopause and cardiovascular disease events. 
However, no evidence of changes in lipid concentrations 
between premenopause and perimenopause was found 
in the NSHD study.51 Fourth, little information was 
available about types and doses of menopausal hormone 
therapy. Nevertheless, one study has found the 
association among different types of menopausal 
hormone therapy (oestrogen alone or oestrogen with 
progestin) and incident coronary heart disease or stroke 
was similar.53 Fifth, menopause status was based on self-
report, which might induce recall bias. However, 
previous studies have shown that the validity and 
reproducibility of self-reported age at meno pause was 
good.54 Also, validated questionnaires and standard 
questions were used in each study; thus we assume the 
heterogeneity of menopause status among studies is 
limited. Sixth, as the outcome of this study was non-fatal 
cardiovascular disease events, the exclusion on fatal 
cardiovascular disease events might bias our results. 
However, since only 7·2% of first cardiovascular disease 
events are fatal,55 and earlier menopause has been 
associated with higher cardiovascular disease mortality,8 
the inclusion of fatal events in the analyses would only 
strengthen the association between earlier age at 
menopause and incident cardiovascular disease. Finally, 
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more than 80% of the women included in our study 
were white, which could limit the generalisability of the 
findings to other ethnicities.
Compared with women with average age at menopause, 
women with premature and early menopause had higher 
risk of a non-fatal cardiovascular disease event with an 
almost linear dose-response relationship for each year of 
decrease in age at menopause. This excess risk was 
highest before the age of 60 years, but was greatly 
diminished by the age of 70 years. A systematic review 
showed that the prevalence of premature (3·7%) and 
early menopause (12·2%) in women is considerable.56 
WHO estimates that 1·2 billion women worldwide will 
be perimenopausal or postmenopausal by the year 2030, 
with 47 million women becoming menopausal each 
year.57 Studies have shown that in the past 30 years, 
cardiovascular disease mortality rates have decreased 
sharply whereas the decrease in incidence has been less 
steep.58,59 Our findings could have important clinical and 
public health implications. First, strategies to reduce the 
risk of early menopause, such as the avoidance of 
cigarette smoking and maintaining a normal BMI, 
provide primary prevention measures for cardiovascular 
disease. Second, identification of women with early 
menopause offers a window of opportunity to implement 
active management of other cardiovascular disease risk 
factors in these women to improve overall cardiovascular 
health in postmenopausal years. These women might 
also need close monitoring in clinical practice. Third, 
early or premature menopause might also be considered 
as an important factor in risk stratification of 
cardiovascular disease. Further research is needed to 
assess the added value of including the timing of 
menopause as a predictor in existing cardiovascular 
disease models for women and to provide physicians 
with a more accurate prediction model for women.
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